Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01)

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
To evaluate the efficacy and safety of SYS6010 versus platinum-based chemotherapy in participants with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)
Epistemonikos ID: a42474cd4d65d0b1bd7a2bf523bb2c15a58a6717
First added on: Apr 16, 2025